Colorectal cancer vaccine - Shanghai Haixin Biotechnology

Drug Profile

Colorectal cancer vaccine - Shanghai Haixin Biotechnology

Alternative Names: APDC - Shanghai Haixin Biotechnology; autologous tumor lysates pulsed human dendritic cells vaccine - Shanghai Haixin Biotechnology

Latest Information Update: 06 Jan 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Shanghai Haixin Biotechnology
  • Developer Second Military Medical University; Shanghai Haixin Biotechnology
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Colorectal cancer

Most Recent Events

  • 17 Feb 2005 Phase-II clinical trials in Colorectal cancer (Metastatic disease, Combination therapy) in China (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top